Highlights | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Views 220
Citations 0
In This Issue of JAMA Ophthalmology
November 2019

Highlights

JAMA Ophthalmol. 2019;137(11):1221. doi:10.1001/jamaophthalmol.2018.4798

Research

Kloosterboer and coauthors evaluate the quality, accuracy, and readability of online information on diabetic retinopathy. In a cross-sectional study, 11 diabetic retinopathy websites were analyzed. All were of poor quality and had a substantial variation in content accuracy and readability. The findings suggest that available online information on diabetic retinopathy typically is not sufficient to support the patient in making appropriate medical decisions.

Invited Commentary

Continuing Medical Education

Hykin and coauthors compared intravitreal aflibercept or bevacizumab in a noninferior trial with ranibizumab for eyes with central retinal vein occlusion–related macular edema. In a randomized clinical trial of 463 individuals with central retinal vein occlusion–related macular edema from 44 UK National Health Service ophthalmology departments, aflibercept treatment was noninferior (no worse than) to ranibizumab treatment at 100 weeks and the results for bevacizumab vs ranibizumab were not noninferior (ie, inconclusive compared with the ranibizumab group). The authors recommend that this information should be considered before treating such cases.

CME and Journal Club

Kolomeyer and coauthors examine the rate of filled opioid prescriptions around the time of incisional ocular surgeries and how that rate changed with time. In a cohort study querying a large national US insurer’s claims database, the authors found an increasing trend of filled opioid prescriptions over the course of all years studied (2000-2016). Race/ethnicity, education, yearly income, and geographic location affected the rate of filled opioid prescriptions. The findings suggest further research may be warranted to study the trend of increasing rates of filled perioperative opioid prescriptions identified in this investigation.

Audio Author Interview

Enoch and coauthors question which sense is most valued by the general public in the United Kingdom. In a cross-sectional online survey, the authors found that sight is the most valued sense, followed by hearing. On average, participants would choose 4.6 years of life in perfect health over 10 years of life with complete sight loss, and members of the public valued balance above traditionally recognized senses, such as touch, taste, and smell. The study supports frequent assertions made by practitioners, researchers, and funding agencies that sight is the most valued sense among the general population of the United Kingdom.

×